Dr. Eroles studied Pharmacy at the Faculty of Pharmacy of the Universitat de València where she graduated in 1994, obtaining the extraordinary degree award. She has a doctorate in this same university in 1999. During his predoctoral training he spent a six-month stay at the Institute of Medical Sciences of the University of Aberdeen (Scotland). After obtaining his doctorate, he moved to the US for four years, doing two postdoctoral stays; first in the Department of Pharmacology of the University of Pennsylvania (Philadelphia) and later the Department of Hematology and Oncology of the Weill Medical College of the University of Cornell (New York).
He returned to Spain in 2004 with a Miguel Servet contract to join the Research Foundation of the Hospital Clínico de Valencia, currently the INCLIVA Research Institute. Since 2009, she has been a stable researcher of the Institute and is part of the Breast Cancer Biology Research Group, where she heads the Laboratory of Cellular and Molecular Oncology.
The research lines of this group are focus on the HER2+ and the triple negative breast cancer subtypes. They are particularly interested in deciphering the mechanisms of resistance to current treatments and for that, they are evaluating the involvement of stem cells, the mesenchymal epithelium transition and the epigenetic modifications (miRNAs and methylation). The main aim is to develop new diagnostic and therapeutic intervention strategies to reverse resistance based on the combination of biological agents and the development of new treatments such as nanoparticles or anti-miRNAs.